The stock of Caris Life Sciences shined in its Nasdaq debut on Wednesday, pricing its heavily-subscribed initial public ...

David Dean Halbert, Caris Life Sciences chairman, founder and CEO, joins 'Squawk Box' to discuss the company's IPO debut, how ...

The cancer diagnostics and treatment company priced shares above their earlier target range and might signal a renewed ...

The successful IPO of Caris Life Sciences makes its founder David Dean Halbert worth an estimated $3.3 billion.

Caris Life Sciences® (Caris), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, ...

Caris Life Sciences Inc., a health-care company that uses technology to help diagnose and treat cancer, raised $494 million ...

Caris Life Sciences Inc., a health care company that uses technology to help diagnose and treat cancer, raised $494 million ...

Caris Life Sciences is experiencing rapid growth, leveraging AI and molecular science for personalized medicine. Click here ...

Cancer-testing company raises $494 million in initial public offering.

Caris Life Sciences (CAI) priced 23.53M shares at $21.00. The deal priced above the $19.00-$20.00 range. BofA, JPMorgan and Goldman Sachs acted as joint book running managers for the offering. Caris ...

Caris Life Sciences bumped up the pricing of its IPO to raise more than $494.1 million in its Nasdaq debut—well over the ...

Caris Life Sciences Inc., a health-care company that uses technology to help diagnose and treat cancer, is seeking to raise ...